Abstract 264P
Background
Cancer-related cognitive impairment (CRCI), affecting up to 80% of breast cancer (BC) patients, manifests in various cognitive domains such as learning, memory, and concentration. The hippocampus, crucial for these cognitive processes and known to retain its neurogenesis capacity throughout adulthood, is susceptible to morphological alterations due to BC treatment. Recent research highlights the link between physical exercise and neurogenesis. This study aims to investigate CRCI and the potential effects of high-intensity interval training (HIIT) on learning, memory, and concentration function, as well as brain morphology in BC patients undergoing treatment.
Methods
This randomized (1:1) controlled trial allocated early-stage BC patients to either a HIIT intervention group (IG) or a control group (CG). The intervention involved a 12-month supervised HIIT program tailored through cardio-pulmonary exercise testing. Learning, memory, and concentration function were assessed using the California Verbal Learning Test (CVLT) alongside the Wechsler Memory Scale (WMS). Hippocampal volume was evaluated with MRI-based free surfer analysis. Assessments were conducted at baseline and after 12 months.
Results
A total of 69 patients (mean age 50.67 years, SD 10.55; 98.5% female) were recruited. The analysis showed no statistically significant changes in total hippocampal volume in either group (IG: p = 0.25 and p = 0.39; CG: p = 0.25 and p = 0.33). Similarly, no significant changes were observed in the CVLT scores for both groups (IG: p = 0.102; CG: p = 0.059). However, compared to the CG, the IG exhibited significant improvements in the WMS (p < 0.05).
Conclusions
Assessing CRCI in BC patients is challenging. Despite a multimodal approach, we couldn't objectify structural or functional adverse effects on specific cognitive subdomains. Although HIIT exercise during chemotherapy didn't notably impact learning and memory, it did enhance concentration over time. This might suggest that cognitive function in BC patients benefits from exercising.
Clinical trial identification
NCT04789187. Registered on 09 March 2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Verein zur Forschungsförderung der Krebshilfe OÖ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
323P - SPEN: Unraveling breast cancer's genetic symphony — Prognostic significance and therapeutic insights
Presenter: Sameer Emeish
Session: Poster session 14
324P - Application of advanced machine learning techniques to improve prognosis in primary breast angiosarcoma
Presenter: Haya Kamal
Session: Poster session 14
Resources:
Abstract
325P - The clinical validity of histological grade in neoadjuvant treated breast cancer
Presenter: Sanna Steen
Session: Poster session 14
326P - Exploratory analysis of the association of systemic inflammation and breast cancer recurrence in the Optitrain randomised controlled trial
Presenter: Marlene Rietz
Session: Poster session 14
327P - Monitoring over time of pathological complete response to neoadjuvant chemotherapy in breast cancer patients through an ensemble vision transformers-based model
Presenter: Maria Colomba Comes
Session: Poster session 14
328P - Real-world evidence (RWE) of effectiveness and safety of TCHP regimen: INSIGHT-HER2BC trial interim results
Presenter: Daur Meretukov
Session: Poster session 14
329P - RANK/RANKL, ERBB-2: A putative dual targeting strategy in RANK+/Her2+ breast carcinomas patients
Presenter: Michalis Karamouzis
Session: Poster session 14
330P - Randomized phase II study of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients
Presenter: Shereef Elsamany Mohammed
Session: Poster session 14
331P - Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
Presenter: Mingxia Jiang
Session: Poster session 14
332P - Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab plus nab-paclitaxel followed by epirubicin/cyclophosphamide for TNBC: A phase II TREND trial
Presenter: yingying Xu
Session: Poster session 14